



1641
ZPW

PATENT
Attorney Reference Number 4239-61854-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Pastan et al.

Application No. 10/031,158

Filed: January 11, 2002

Confirmation No. 8170

For: T-CELL RECEPTOR Y ALTERNATE
READING FRAME PROTEIN, (TARP)
AND USES THEREOF

Examiner: Stephen L. Rawlings, Ph.D.

Art Unit: 1641

Attorney Reference No. 4239-61854-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed July 22, 2004

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- Supplemental Information Disclosure Statement
 - Form 1449 and copies of the references cited thereon
- The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

TRANSMITTAL - Page 1 of 1



07/22/04 4239-61854-01 295959

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Pastan et al.

Application No. 10/031,158

Filed: January 11, 2002

Confirmation No. 8170

For: T-CELL RECEPTOR Y ALTERNATE
READING FRAME PROTEIN, (TARP)
AND USES THEREOF

Examiner: Stephen L. Rawlings, Ph.D.

Art Unit: 1641

Attorney Reference No. 4239-61854-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed July 22, 2004

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(3)**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.


Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first substantive Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of the transmittal sheet for this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Susan Alpert Siegel, Ph.D.
Registration No. 43,121

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446



**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Attorney Docket No.	4239-61854-01
Application Number	10/031,158
Filing Date	January 11, 2002
First Named Inventor	Pastan
Art Unit	1641
Examiner Name	Stephen L. Rawlings, Ph.D.

Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS
		Oh <i>et al.</i> , "Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells," <i>Cancer Res.</i> 64(7):2610-2618, 2004 (abstract only)
		Wolfgang <i>et al.</i> , "T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin," <i>Cancer Res.</i> 61(22):8122-8126, 2001 (abstract only)
		GenBank Accession No. AAG29337
		GenBank Accession No. AI557112
		GenBank Accession No. CAA51166
		GenBank Accession No. M27334
		GenBank Accession No. X72500

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.